ストックスクリーナーアプリを入手
19.69
10.12%
1.81
前日終値:
$17.88
開ける：
$18.29
24時間の取引高:
1.07M
Relative Volume:
1.05
時価総額：
$1.93B
収益：
$577.74M
当期純損益:
$-149.78M
株価収益率:
-10.59
EPS:
-1.86
ネットキャッシュフロー:
$-78.21M
1週間 パフォーマンス:
+16.79%
1か月 パフォーマンス:
+17.62%
6か月 パフォーマンス:
-14.95%
1年 パフォーマンス:
+65.32%
1日の値動き範囲:
$18.00
$19.77
1週間の範囲:
$16.30
$19.77
52週間の値動き範囲:
$11.29
$24.73
Novocure Ltd Stock (NVCR) Company Profile
NVCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
19.69 | 1.93B | 577.74M | -149.78M | -78.21M | -1.86 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 開始されました | SVB Securities | Outperform |
| 2023-07-31 | アップグレード | Evercore ISI | Underperform → In-line |
| 2023-06-07 | アップグレード | Wedbush | Underperform → Neutral |
| 2023-05-16 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-11-29 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-08 | 開始されました | Loop Capital | Buy |
| 2022-02-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2022-01-03 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-07-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-14 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-01-25 | 繰り返されました | Piper Sandler | Overweight |
| 2020-09-23 | 開始されました | Northland Capital | Outperform |
| 2020-09-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | ダウングレード | Truist | Buy → Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Perform |
| 2020-05-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-04-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-03-05 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-29 | アップグレード | SunTrust | Hold → Buy |
| 2019-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-07-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2018-11-02 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 開始されました | Evercore ISI | Outperform |
| 2018-04-18 | 繰り返されました | Mizuho | Buy |
| 2018-02-23 | 繰り返されました | Mizuho | Buy |
| 2017-05-24 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 繰り返されました | Wedbush | Outperform |
| 2016-01-19 | 開始されました | Barclays | Underweight |
| 2015-12-02 | 開始されました | Deutsche Bank | Hold |
すべてを表示
Novocure Ltd (NVCR) 最新ニュース
NVCR (NovoCure) Shares Outstanding (EOP) : 108.1 Mil (As of Sep. 2024) - GuruFocus.com
Novocure's SWOT analysis: FDA approval boosts cancer tech stock prospects - Investing.com
NovoCure (NASDAQ:NVCR) Receives Buy Rating from HC Wainwright - Defense World
NVCR (NovoCure) Growth Rank : 8 (As of Nov. 24, 2024) - GuruFocus.com
Connor Clark & Lunn Investment Management Ltd. Acquires 59,608 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
FDA approves Novocure's new device for brain cancer treatment By Investing.com - Investing.com South Africa
Novocure secures FDA approval for add-ons to brain cancer treatment wearable - Yahoo Finance
Novocure’s HFE Transducer Arrays OK’ed with Optune Gio for Glioblastoma - MPO-mag
FDA approves Novocure's new device for brain cancer treatment - Investing.com
Novocure to Present Breakthrough TTFields Brain Cancer Treatment Data at SNO Meeting | NVCR Stock News - StockTitan
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma - Yahoo Finance
Can Novocure's PANOVA-3 Trial Of TTFields Therapy Electrify The Stock? - RTTNews
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NovoCure (NVCR) Shares Cross Below 200 DMA - Nasdaq
NovoCure Ltd (NVCR) Trading Down 2.79% on Nov 14 - GuruFocus.com
Baillie Gifford & Co. Sells 28,207 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Analyze NovoCure Ltd (NASDAQ: NVCR) Before Investing. - Stocks Register
Nordwand Advisors LLC Buys 1,514,824 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure Ltd (NVCR) Shares Up 3.63% on Nov 8 - GuruFocus.com
Novocure's oncology president sells $9,530 in shares - Investing.com India
Novocure's COO Mukund sells shares worth $2,540 By Investing.com - Investing.com Canada
Novocure's COO Mukund sells shares worth $2,540 - Investing.com India
Michal Nath Puri Sells 810 Shares of NovoCure Limited (NASDAQ:NVCR) Stock - MarketBeat
Novocure's oncology president sells $9,530 in shares By Investing.com - Investing.com Australia
NovoCure Ltd (NVCR) Shares Up 3.96% on Nov 4 - GuruFocus.com
FY2024 EPS Estimates for NovoCure Lifted by HC Wainwright - MarketBeat
Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report - Simply Wall St
NovoCure Limited (NASDAQ:NVCR) Q3 2024 Earnings Call Transcript - Insider Monkey
NovoCure shares hold Buy rating, steady price target post-earnings - Investing.com
NovoCure shares hold Buy rating, steady price target post-earnings By Investing.com - Investing.com UK
NovoCure's (NVCR) Buy Rating Reiterated at HC Wainwright - MarketBeat
NovoCure’s Strong Q3 and Leadership Changes in 2024 - Yahoo Finance
NovoCure: Q3 Earnings Snapshot - Milford Mirror
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - Yahoo Finance
Novocure names Christoph Brackmann as new CFO - Investing.com India
Novocure’s Q3 2024 Results Highlight Growth and Innovation - TipRanks
NovoCure (NASDAQ:NVCR) Stock Price Down 7.1%Should You Sell? - MarketBeat
Novocure Ltd earnings beat by $0.05, revenue topped estimates - Investing.com
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Novocure Appoints Christoph Brackmann as Chief Financial Officer - Yahoo Finance
Novocure Reports Third Quarter 2024 Financial Results - Yahoo Finance
Semanteon Capital Management LP Makes New Investment in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure (NVCR) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Brokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $26.17 - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Shares Sold by SG Americas Securities LLC - MarketBeat
Novocure shares soar 33% as FDA approves lung cancer treatment - MSN
Leerink Partnrs Forecasts Stronger Earnings for NovoCure - MarketBeat
NovoCure scoops FDA approval on wearable for metastatic cancer treatment - Medical Device Network
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment - Yahoo Finance
Novocure Ltd (NVCR) 財務データ
収益
当期純利益
現金流量
EPS
Novocure Ltd (NVCR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Puri Michal Nath | Chief Human Resources Officer |
Oct 31 '24 |
Sale |
15.79 |
810 |
12,792 |
110,093 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Nov 01 '24 |
Sale |
15.94 |
598 |
9,531 |
161,236 |
| Paravasthu Mukund | Chief Operating Officer |
Nov 01 '24 |
Sale |
15.88 |
160 |
2,540 |
3,503 |
| Cordova Ashley | Chief Financial Officer |
Aug 02 '24 |
Sale |
20.14 |
688 |
13,857 |
219,179 |
| GROENHUYSEN WILHELMUS CM | Chief Operating Officer |
Jun 05 '24 |
Option Exercise |
22.82 |
124,373 |
2,838,192 |
124,373 |
| VERNON W ANTHONY | Director |
Jun 04 '24 |
Sale |
23.89 |
964 |
23,033 |
164,833 |
| Scannell Timothy J | Director |
Jun 04 '24 |
Sale |
23.89 |
964 |
23,027 |
2,964 |
| LEUNG GABRIEL | Director |
Jun 04 '24 |
Sale |
23.89 |
964 |
23,025 |
78,175 |
| GROENHUYSEN WILHELMUS CM | Chief Operating Officer |
Mar 01 '24 |
Sale |
16.03 |
2,107 |
33,769 |
252,452 |
| GROENHUYSEN WILHELMUS CM | Chief Operating Officer |
Mar 04 '24 |
Sale |
16.01 |
1,217 |
19,484 |
251,235 |
0.65%
大文字化:
|
ボリューム (24 時間):